Artificial Intelligence driven Marketing Communications
Activiomics Ltd. has developed a groundbreaking and patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled.
Activiomics’ technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Phosphorylation is critical mediator all cellular processes and hence sites of phosphorylation represent an important class of novel biomarkers. Activiomics’ TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics.
Graeme Brown joined Queen Mary University of London in 2002 as Business Development Manager. Since May 2005 he has been Director of Technology Transfer for Queen Mary, leading a team responsible for the management and exploitation of the Colleges intellectual property portfolio. Graeme has broad experience of technology licensing, securing equity investment in spinout companies, and sits on the advisory boards of Kinetique Biomedical Seed Fund and Heptagon Life Science Proof of Concept Fund.
Bart Vanhaesebroeck is Professor in Cell Signalling at Barts & the London Medical School at Queen Mary University of London. In 2007, he set up the new Centre for Cell Signalling which studies signal transduction in the broadest sense. He is a world leading expert in PI 3-kinase signalling, a major disease target in oncology and inflammatory diseases. Bart has extensive interactions with Industry at the academic, commercial and consultancy level. He has PhD in Biology/Molecular Biology from Ghent University, in Belgium and previously held positions at the Ludwig Institute for Cancer Research, London and University College London.
Dr Pedro Cutillas joined the Institute of Cancer as Head of Analytical Signalling in June 2007, following on from postdoctoral work in Bart Vanhaesebroecks laboratory at the Ludwig Institute for Cancer Research London. His focus of research involves the use of MS and related analytical techniques to quantify the activity of cell signalling pathways. He holds a PhD in biological mass spectrometry from the laboratory of Mike Waterfield, UCL, and was co-supervised by
Al Burlingame and Robert Unwin. Pedro conceived the core technologies of Activiomics and has developed unique knowledge and expertise in the use of these MS-based analytical techniques. This makes him uniquely positioned to bridge the gap between modern analytical technologies and their biological application.
Mark has been with IP Group since 2008 identifying and commercialising intellectual property in the life science arena from UK universities. He also manages IP Groups partnerships with the Universities of Oxford, Bristol and Bath. In addition, Mark undertakes both executive and non-executive functions for a number of IP Group life science portfolio companies.
Mark joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.